VSTM Verastem, Inc.
$10.10▲ +1.00%
Healthcare
Other
After hours
$10.00▼ -0.99%
Oct 27, 4:46 PM ET
Volume 4.70M
Avg Volume (10D) 8.47M
Key Metrics & Fundamentals
Market Cap
$1.23B
P/E Ratio
–
Div Yield
0.00%
52W Range
3.43 - 10.82
% vs 50 MA
26.22%
% vs 200 MA
64.80%
RSI-14
67.4
MACD Histogram
+0.1700
Beta (1Y vs SPY)
1.02
Free Cash Flow
-$43.91M
Gross Rev
$40.08M
Gross Profit
$36.04M
EBITDA
-$33.22M
COGS
$4.04M
Operating Exp
$68.75M
Operating Income
-$32.71M
EBIT
-$32.71M
Pretax Income
-$33.86M
Net Income
-$34.67M
EPS (Diluted)
-0.35
Price & Volume History
Loading chart…
Recent News
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
Zacks · Oct 27, 2026 7:50 AM ET
What Verastem (VSTM)'s Trial Update Means For Shareholders
Simply Wall St. · Oct 23, 2026 10:10 PM ET
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
Business Wire · Oct 22, 2026 7:30 AM ET
Verastem (VSTM) Shares Jumped On Trial Data And Funding, Is The Stock Still Cheap?
Simply Wall St. · Oct 15, 2026 9:12 PM ET
VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes
Stocktwits · Oct 15, 2026 5:00 PM ET
Sector Update: Healthcare Stocks Gain Thursday Afternoon
MT Newswires · Oct 15, 2026 1:54 PM ET
Sector Update: Healthcare
MT Newswires · Oct 15, 2026 1:19 PM ET
Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says
MT Newswires · Oct 15, 2026 12:27 PM ET
Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC
Clinical Trials Arena · Oct 15, 2026 12:22 PM ET
Mizuho Raises Price Target on Verastem to $14 From $13, Keeps Outperform Rating
MT Newswires · Oct 15, 2026 7:57 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See VSTM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.